Natera withdraws appeal in NeoGenomics patent case

Natera has voluntarily withdrawn its appeal of a North Carolina District Court ruling that favored NeoGenomics (NASDAQ: NEO) in patent litigation related to molecular residual disease testing technology.

The August 2025 ruling by the District Court for the Middle District of North Carolina granted NeoGenomics' motion for summary judgment and determined that Natera's patent claims were invalid for claiming ineligible subject matter. The court dismissed Natera's claims against NeoGenomics with prejudice and entered a declaratory judgment of invalidity regarding both of Natera's asserted patents.

With Natera's withdrawal of its appeal, NeoGenomics also dismissed its cross-appeal, leaving the original ruling in place. The litigation centered on NeoGenomics' RaDaR molecular residual disease assay technology.

"We are very pleased that Natera has voluntarily decided to end this litigation process," said Tony Zook, CEO of NeoGenomics. "While we were confident in our position, this latest development nonetheless allows us to focus our full attention on executing a robust clinical launch of RaDaR ST in the first quarter of next year."

NeoGenomics plans to move forward with a full U.S. clinical launch of its RaDaR ST molecular residual disease assay in the first quarter of 2026. The company provides oncology diagnostic solutions and operates laboratories throughout the United States and in Cambridge, United Kingdom.

The information is based on a company press release statement.

You May Also Be Interested In

• Takeda names Julie Kim as president and CEO after shareholder vote
• Citizens Starts MARA Holdings Inc (MARA) at Market Outperform
• Morgan Stanley Upgrades Global Unichip Corp (3443:TT) to Overweight